Hematology
News
Drugs
Xagena Medicine
Xagena.net
Relapsed or refractory multiple myeloma: clinical benefits with Lenalidomide,
MRD-negative remission with MabCampath improves survival in patients with chronic lymphocytic leucemia
Europe: Velcade as a second-line treatment of multiple myeloma
Childhood leukemia: protection from exposure to infections in early life
Multiple myeloma: FDA has approved Velcade as second-line
B-cell non-Hodgkin's lymphoma and HCV infection: role of hepatitis C treatment
Follicular non-Hodgkin’s lymphoma: MabThera plus short-duration chemotherapy as first-line treatment
Relapsed or refractory B-cell non-Hodgkin's lymphoma: Velcade
Relapsed or refractory multiple myeloma: efficacy of Revlimid
TNF blockers linked to lymphoma risk
Next Pages
1
2
[
3
]
Web
Xagena News
Link
•
Allergology
•
Andrology
•
Biomedicine
•
Cardiology
•
Dermatology
•
Diabetology
•
Diagnostics
•
Drugs
•
Endocrinology
•
Gastroenterology
•
Gene Medicine
•
Gynecology
•
Hematology
•
Hepatology
•
Infectivology
•
Metabolism
•
Nephrology
•
Neurology
•
Oncology
•
Ophthalmology
•
Pediatrics
•
Pharmacology
•
Pneumology
•
Psychiatry
•
Rheumatology
•
Stem Therapy
•
Urology
•
Vaccines
•
Virology
n
Xagena.it
Powered by Luca Malattia -
LM Web Solutions
